Abstract
Çin'de Şiddetli Akut Solunum Yetmezliği Sendromu-Coronavirus-2'nin (SARS-CoV-2) neden olduğu COVID-19 enfeksiyonu tüm dünya çapında bir pandemiye yol açmıştır. Ölüm oranı %4,3-14,6 arasında değişmekle birlikte, çalışmalar koagülasyon disfonksiyonunun ağır COVID-19 enfeksiyonu olan hastalarda önemli bir ölüm nedeni olduğunu ortaya koymuştur. Ağır hastaların çoğunda altta yatan bir hastalık (diyabet, kardiyovasküler hastalık, hipertansiyon) vardır ve başlangıçta solunum yetmezliği ortaya çıkar, ancak bazıları çoklu organ disfonksiyonuna neden olan sistemik hastalığa ilerler. Bu yazıda COVID-19 enfeksiyonu olan hastalardaki koagülasyon sistemi bozuklukları tartışılmaktadır.
References
- 1- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. 2- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. 3- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844- 847. 4- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020. Doi:10.1001/jamainternmed.2020.0994. 5- Fogarty H, Townsend L, Cheallaigh CN, et al. COVID-19 Coagulopathy in Caucasian patients. Br J Haematol 2020, doi.org/10.1111/bjh.16749. 6- Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517–28. 7- Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost 2018;16:231-41. 8- Iba T, Levy JH, Wada H, et al. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost 2019;17:415-9. 9- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. 10.1001/jama.2020.1585. 10- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62. 11- Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020. 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. 12- Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020. doi: 10.1111/jth.14854. 13- Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 doi: 10.1182/blood.2020006000. 14- Fox SE, Akmatbekov A, Harbert JL, Li G, et al. Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans. medRxiv 2020.04.06.20050575; doi: https://doi.org/10.1101/2020.04.06.20050575. 15- Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020. 395(10234):1417-1418 doi: 10.1016/S0140-6736(20)30937-5. 16- Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. doi: 10.1016/j.thromres.2020.04.013. 17- Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020 doi:10.1111/jth.14830. 18- Song JC, Wang G, Zhang W, Zhang Y, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020 .20;7(1):19. doi: 10.1186/s40779-020-00247-7. 19- Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026. doi: 10.1111/jth.14810. 20- Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5):1094-1099. doi: 10.1111/jth.14817. 21- Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID -19. Thromb Res, 2020. doi:https://doi.org/10.1016/j.thromres.2020.04.013. 22- Lodigiani C, Iapichino G, Carenzo L, Cecconi M, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020. 23;191:9-14. doi: 10.1016/j.thromres.2020.04.024 23- Iba T, Arakawa M, Ohchi Y, et al. Prediction of Early Death in Patients With SepsisAssociated Coagulation Disorder Treated With Antithrombin Supplementation. Clin Appl Thromb Hemost 2018:1076029618797474. 24- Wang J, Hajizadeh N, Moore EE, McIntyre RC, et al. Tissue Plasminogen Activator (tPA) Treatment for COVID‐19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series. J Thromb Haemost. 2020 doi:10.1111/jth.14828. 25- Hadem J, Hafer C, Schneider AS, Wiesner O, Beutel G, Fuehner T, et al. Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-center study of 23 patients. BMC Anesthesiol. 2014;14:24. 26- T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü COVID-19 (SARS-CoV-2 Enfeksiyonu) Rehberi. 12 Nisan 2020, 64-68.
Abstract
COVID-19 infection caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) in China led to a pandemic all over the world. Although mortality rate between 4.3% to 14.6%, studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19 infection. The majority of the severely ill patients have underlying disease (i.e. diabetes, cardiovascular disease, hypertension) and initially present with respiratory insufficiency but some of them progress to systemic disease causing multiple organ dysfunction. This manuscript reviews coagulation system abnormalities in patients with COVID-19 infection.
References
- 1- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. 2- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. 3- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844- 847. 4- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020. Doi:10.1001/jamainternmed.2020.0994. 5- Fogarty H, Townsend L, Cheallaigh CN, et al. COVID-19 Coagulopathy in Caucasian patients. Br J Haematol 2020, doi.org/10.1111/bjh.16749. 6- Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517–28. 7- Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost 2018;16:231-41. 8- Iba T, Levy JH, Wada H, et al. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost 2019;17:415-9. 9- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. 10.1001/jama.2020.1585. 10- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62. 11- Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020. 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. 12- Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020. doi: 10.1111/jth.14854. 13- Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 doi: 10.1182/blood.2020006000. 14- Fox SE, Akmatbekov A, Harbert JL, Li G, et al. Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans. medRxiv 2020.04.06.20050575; doi: https://doi.org/10.1101/2020.04.06.20050575. 15- Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020. 395(10234):1417-1418 doi: 10.1016/S0140-6736(20)30937-5. 16- Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. doi: 10.1016/j.thromres.2020.04.013. 17- Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020 doi:10.1111/jth.14830. 18- Song JC, Wang G, Zhang W, Zhang Y, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020 .20;7(1):19. doi: 10.1186/s40779-020-00247-7. 19- Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026. doi: 10.1111/jth.14810. 20- Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5):1094-1099. doi: 10.1111/jth.14817. 21- Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID -19. Thromb Res, 2020. doi:https://doi.org/10.1016/j.thromres.2020.04.013. 22- Lodigiani C, Iapichino G, Carenzo L, Cecconi M, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020. 23;191:9-14. doi: 10.1016/j.thromres.2020.04.024 23- Iba T, Arakawa M, Ohchi Y, et al. Prediction of Early Death in Patients With SepsisAssociated Coagulation Disorder Treated With Antithrombin Supplementation. Clin Appl Thromb Hemost 2018:1076029618797474. 24- Wang J, Hajizadeh N, Moore EE, McIntyre RC, et al. Tissue Plasminogen Activator (tPA) Treatment for COVID‐19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series. J Thromb Haemost. 2020 doi:10.1111/jth.14828. 25- Hadem J, Hafer C, Schneider AS, Wiesner O, Beutel G, Fuehner T, et al. Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-center study of 23 patients. BMC Anesthesiol. 2014;14:24. 26- T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü COVID-19 (SARS-CoV-2 Enfeksiyonu) Rehberi. 12 Nisan 2020, 64-68.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | REVIEW |
| Authors | |
| Publication Date | July 24, 2020 |
| Submission Date | June 25, 2020 |
| Published in Issue | Year 2020 COVID-19 |
The publication language of Turkish Journal of Pediatric Disease is English.
Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 10 original articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.
The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.